Mirina, the microRNA drug developer at Accelerator, raised $3.9 million in its “expansion round” of financing that was reported earlier this week, according to a regulatory filing. The money ought to be enough to operate the company inside Accelerator for another 12-15 months as the company seeks to nail down more intellectual property around some advantages of its microRNA therapies, says Accelerator CEO Carl Weissman. Brian Atwood of Versant Ventures has joined the Mirina board, which also includes Weissman, Thong Le of WRF Capital, Steve Gillis of Arch Venture Partners, Chad Waite of OVP Venture Partners, Merl Hoekstra of Elitech Group, according to the filing.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
